Novamind and Wholeness Center partner on a psychedelic therapy protocol for frontline healthcare workers
Group ketamine therapy for healthcare workers with Covid-based stress & trauma led by Dr. Scott Shannon and Dr. Reid Robison
Learn moreInvestor relations
We are a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.
Press releases
June 17, 2021
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
June 15, 2021
Novamind to Present at the H.C. Wainwright Psychedelics Conference on June 17, 2021
June 10, 2021
Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers
June 01, 2021
Novamind Reports Fiscal Q3 Financial Results and Operating Highlights
Financial statements
| Year | Quarter | Date | Report | Download |
|---|---|---|---|---|
| 2021 | Q3 | June 1, 2021 | Interim Financial Statements | View PDF |
| 2021 | Q3 | June 1, 2021 | Management’s Discussion and Analysis | View PDF |
| 2021 | Q2 | March 1, 2021 | Interim Financial Statements | View PDF |
| 2021 | Q2 | March 1, 2021 | Management’s Discussion and Analysis | View PDF |
Q3 • 2021
Q3 • 2021
Q2 • 2021
Q2 • 2021
Fiscal year end is June 30th. To view Novamind's full financial disclosures, please visit SEDAR
Advisors
Transfer agent
Marrelli Trust Company Limited
Legal Counsel
McMillan LLP
Auditor
DMCL LLP
Interested in investing? Contact IR@novamind.ca